Analyst Price Targets — EVFM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2022 12:00 am | Jeffrey Hung | Morgan Stanley | $66.25 | $55.00 | Pulse 2.0 | Evofem Biosciences (EVFM) Stock: $0.53 Price Target And Underweight Rating |
Latest News for EVFM
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals, LLC, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize SOLOSEC® (secnidazole) 2g oral granules in sub-Saharan Africa (the Territory). SOLOSEC…
Valuation and Earnings This table compares Ayala Pharmaceuticals and Evofem Biosciences"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ayala Pharmaceuticals $3.24 million 11.05 -$48.07 million ($5.02) -0.12 Evofem Biosciences $11.39 million 0.10 $52.98 million ($0.03) -0.28 Evofem Biosciences has higher revenue and earnings
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health pioneer Evofem reported its fifth consecutive year of top line growth, with 2025 net product sales of more than $20 million.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EVFM.
U.S. House Trading
No House trades found for EVFM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.